These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 36170570)

  • 1. Linker-Dependent Folding Rationalizes PROTAC Cell Permeability.
    Poongavanam V; Atilaw Y; Siegel S; Giese A; Lehmann L; Meibom D; Erdelyi M; Kihlberg J
    J Med Chem; 2022 Oct; 65(19):13029-13040. PubMed ID: 36170570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Solution Conformations Shed Light on PROTAC Cell Permeability.
    Atilaw Y; Poongavanam V; Svensson Nilsson C; Nguyen D; Giese A; Meibom D; Erdelyi M; Kihlberg J
    ACS Med Chem Lett; 2021 Jan; 12(1):107-114. PubMed ID: 33488971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging Strategies in Proteolysis-Targeting Chimeras (PROTACs): Highlights from 2022.
    Tamatam R; Shin D
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural-based design of HD-TAC7 PROteolysis TArgeting chimeras (PROTACs) candidate transformations to abrogate SARS-CoV-2 infection.
    Zahid S; Ali Y; Rashid S
    J Biomol Struct Dyn; 2023; 41(23):14566-14581. PubMed ID: 36841549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PROTACs: A novel strategy for cancer therapy.
    Liu J; Ma J; Liu Y; Xia J; Li Y; Wang ZP; Wei W
    Semin Cancer Biol; 2020 Dec; 67(Pt 2):171-179. PubMed ID: 32058059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteolysis-targeting chimeras (PROTACs) in cancer therapy.
    Li X; Pu W; Zheng Q; Ai M; Chen S; Peng Y
    Mol Cancer; 2022 Apr; 21(1):99. PubMed ID: 35410300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of PROTAC Linker Plasticity on the Solution Conformations and Dissociation of the Ternary Complex.
    Weerakoon D; Carbajo RJ; De Maria L; Tyrchan C; Zhao H
    J Chem Inf Model; 2022 Jan; 62(2):340-349. PubMed ID: 35018781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of Stabilized Peptide-Based PROTACs against Estrogen Receptor α.
    Jiang Y; Deng Q; Zhao H; Xie M; Chen L; Yin F; Qin X; Zheng W; Zhao Y; Li Z
    ACS Chem Biol; 2018 Mar; 13(3):628-635. PubMed ID: 29271628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances and perspectives of proteolysis targeting chimeras (PROTACs) in drug discovery.
    Xi JY; Zhang RY; Chen K; Yao L; Li MQ; Jiang R; Li XY; Fan L
    Bioorg Chem; 2022 Aug; 125():105848. PubMed ID: 35533582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics.
    Khan S; He Y; Zhang X; Yuan Y; Pu S; Kong Q; Zheng G; Zhou D
    Oncogene; 2020 Jun; 39(26):4909-4924. PubMed ID: 32475992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PROTAC-DB: an online database of PROTACs.
    Weng G; Shen C; Cao D; Gao J; Dong X; He Q; Yang B; Li D; Wu J; Hou T
    Nucleic Acids Res; 2021 Jan; 49(D1):D1381-D1387. PubMed ID: 33010159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PROTACs and Building Blocks: The 2D Chemical Space in Very Early Drug Discovery.
    Ermondi G; Garcia-Jimenez D; Caron G
    Molecules; 2021 Jan; 26(3):. PubMed ID: 33525371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A High-Throughput Method to Prioritize PROTAC Intracellular Target Engagement and Cell Permeability Using NanoBRET.
    Vasta JD; Corona CR; Robers MB
    Methods Mol Biol; 2021; 2365():265-282. PubMed ID: 34432249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteolysis-targeting chimeras for targeting protein for degradation.
    Qi J; Zhang G
    Future Med Chem; 2019 Apr; 11(7):723-741. PubMed ID: 30706727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disordered region of cereblon is required for efficient degradation by proteolysis-targeting chimera.
    Kim K; Lee DH; Park S; Jo SH; Ku B; Park SG; Park BC; Jeon YU; Ahn S; Kang CH; Hwang D; Chae S; Ha JD; Kim S; Hwang JY; Kim JH
    Sci Rep; 2019 Dec; 9(1):19654. PubMed ID: 31873151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Understanding and Improving the Membrane Permeability of VH032-Based PROTACs.
    Klein VG; Townsend CE; Testa A; Zengerle M; Maniaci C; Hughes SJ; Chan KH; Ciulli A; Lokey RS
    ACS Med Chem Lett; 2020 Sep; 11(9):1732-1738. PubMed ID: 32939229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Developing PROteolysis TArgeting Chimeras (PROTACs) for hematologic malignancies.
    Wu Y; Zhang J; Zhu X; Zhang Y
    Cancer Lett; 2022 Sep; 544():215808. PubMed ID: 35764266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis and biological evaluation of Proteolysis Targeting Chimeras (PROTACs) as a BTK degraders with improved pharmacokinetic properties.
    Jaime-Figueroa S; Buhimschi AD; Toure M; Hines J; Crews CM
    Bioorg Med Chem Lett; 2020 Feb; 30(3):126877. PubMed ID: 31879210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Buchwald-Hartwig Protocol to Enable Rapid Linker Exploration of Cereblon E3-Ligase PROTACs*.
    Hayhow TG; Borrows REA; Diène CR; Fairley G; Fallan C; Fillery SM; Scott JS; Watson DW
    Chemistry; 2020 Dec; 26(70):16818-16823. PubMed ID: 32706492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies.
    He Y; Khan S; Huo Z; Lv D; Zhang X; Liu X; Yuan Y; Hromas R; Xu M; Zheng G; Zhou D
    J Hematol Oncol; 2020 Jul; 13(1):103. PubMed ID: 32718354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.